IL254842B - Therapeutic preparations and methods for use in cancer treatment - Google Patents
Therapeutic preparations and methods for use in cancer treatmentInfo
- Publication number
- IL254842B IL254842B IL254842A IL25484217A IL254842B IL 254842 B IL254842 B IL 254842B IL 254842 A IL254842 A IL 254842A IL 25484217 A IL25484217 A IL 25484217A IL 254842 B IL254842 B IL 254842B
- Authority
- IL
- Israel
- Prior art keywords
- methods
- treating cancer
- therapeutic compositions
- therapeutic
- compositions
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01057—Phosphatidylinositol alpha-mannosyltransferase (2.4.1.57)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01087—N-Acetyllactosaminide 3-alpha-galactosyltransferase (2.4.1.87), i.e. alpha-1,3-galactosyltransferase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10371—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16671—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1505860.5A GB201505860D0 (en) | 2015-04-07 | 2015-04-07 | Therapeutic compositions and methods of use for treating cancer |
| PCT/GB2016/050973 WO2016162675A1 (en) | 2015-04-07 | 2016-04-07 | Therapeutic compositions and methods of use for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL254842A0 IL254842A0 (en) | 2017-12-31 |
| IL254842B true IL254842B (en) | 2022-01-01 |
Family
ID=53190234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL254842A IL254842B (en) | 2015-04-07 | 2017-10-02 | Therapeutic preparations and methods for use in cancer treatment |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20180104288A1 (https=) |
| EP (1) | EP3280798B1 (https=) |
| JP (2) | JP2018512150A (https=) |
| KR (1) | KR102544032B1 (https=) |
| CN (1) | CN107787364A (https=) |
| BR (1) | BR112017021700A2 (https=) |
| CA (1) | CA2981925C (https=) |
| ES (1) | ES2743952T3 (https=) |
| GB (1) | GB201505860D0 (https=) |
| HK (1) | HK1251009B (https=) |
| IL (1) | IL254842B (https=) |
| MX (1) | MX377211B (https=) |
| RU (1) | RU2720984C2 (https=) |
| WO (1) | WO2016162675A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| KR102608590B1 (ko) | 2014-09-24 | 2023-12-01 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양 살상 바이러스 및 이의 사용방법 |
| WO2017147269A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| EP3532082A4 (en) | 2016-12-12 | 2020-08-26 | Salk Institute for Biological Studies | SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES |
| CN112292449A (zh) | 2018-04-09 | 2021-01-29 | 萨克生物研究学院 | 具有增强的复制特性的溶瘤腺病毒组合物 |
| CN110856724B (zh) * | 2018-08-24 | 2022-05-27 | 杭州康万达医药科技有限公司 | 包含核酸及car修饰的免疫细胞的治疗剂及其应用 |
| US20220249127A1 (en) * | 2019-05-14 | 2022-08-11 | Oncolys Biopharma Inc. | Method for administering oncolytic virus to tumor tissue, and device for administration |
| EP4087920A4 (en) * | 2020-01-10 | 2024-02-28 | The University of Hong Kong | Recombinant viruses expressing alpha-1, 3-galactosyltransferase and uses thereof |
| CA3199581A1 (en) * | 2020-11-30 | 2022-06-02 | Neil H. Bander | Cancer immunotherapies to promote hyperacute rejection |
| CN112941039A (zh) * | 2021-02-01 | 2021-06-11 | 南京大学 | 一种新型类囊泡溶瘤病毒及其在制备抗肿瘤药物上的应用 |
| WO2026068773A1 (en) * | 2024-09-27 | 2026-04-02 | Repudio Ab | Immunotherapy using ggta and nap |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9615794D0 (en) | 1996-07-26 | 1996-09-04 | Medical Res Council | Mutant herpes simplex virus strains and uses thereof |
| US5998174A (en) | 1997-05-12 | 1999-12-07 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Multigene vectors |
| GB9810904D0 (en) | 1998-05-20 | 1998-07-22 | Univ London | Mutant herpes simplex viruses and uses thereof |
| GB2375113B (en) | 2000-01-21 | 2004-10-20 | Biovex Ltd | A modified, oncolytic, non-laboratory HSV strain and its use in treating cancer |
| US7338932B2 (en) * | 2000-05-11 | 2008-03-04 | Glycozym Aps | Methods of modulating functions of polypeptide GalNAc-transferases and of screening test substances to find agents herefor, pharmaceutical compositions comprising such agents and the use of such agents for preparing medicaments |
| AU2002235141A1 (en) | 2000-11-27 | 2002-06-03 | Geron Corporation | Glycosyltransferase vectors for treating cancer |
| US20030099616A1 (en) * | 2001-07-25 | 2003-05-29 | Irving John M. | Dual specificity tumor killing vectors driven by the telomerase promoter |
| CN1756568A (zh) * | 2002-10-09 | 2006-04-05 | 衣阿华中央卫生系统 | 使用表达α(1,3)－半乳糖基转移酶的同种异型肿瘤细胞的抗肿瘤免疫 |
| US20050201993A1 (en) * | 2002-10-09 | 2005-09-15 | Link Charles J.Jr. | Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase |
| JP2008519590A (ja) * | 2004-11-12 | 2008-06-12 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 組換えニューカッスル病ウィルス |
| US7820628B2 (en) | 2005-02-22 | 2010-10-26 | University Of Massachusetts Medical School | Tumor lesion regression and conversion in situ into autologous tumor vaccines by compositions that result in anti-Gal antibody binding |
| EP2085092A1 (en) * | 2008-01-29 | 2009-08-05 | Bayer Schering Pharma Aktiengesellschaft | Attenuated oncolytic paramyxoviruses encoding avian cytokines |
| ES2385251B1 (es) * | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
| ES2733211T3 (es) * | 2011-04-15 | 2019-11-28 | Genelux Corp | Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas |
| KR20150093775A (ko) * | 2012-12-07 | 2015-08-18 | 노쓰 캐롤라이나 스테이트 유니버시티 | 베타 헥소실-전이효소 및 이의 이용 |
| CN105779397B (zh) * | 2014-12-22 | 2019-07-19 | 彭霞 | 溶瘤异源重组新城疫病毒及其制备方法与应用 |
-
2015
- 2015-04-07 GB GBGB1505860.5A patent/GB201505860D0/en not_active Ceased
-
2016
- 2016-04-07 US US15/564,774 patent/US20180104288A1/en not_active Abandoned
- 2016-04-07 ES ES16716896T patent/ES2743952T3/es active Active
- 2016-04-07 KR KR1020177027601A patent/KR102544032B1/ko active Active
- 2016-04-07 CA CA2981925A patent/CA2981925C/en active Active
- 2016-04-07 MX MX2017012867A patent/MX377211B/es active IP Right Grant
- 2016-04-07 RU RU2017134519A patent/RU2720984C2/ru active
- 2016-04-07 EP EP16716896.2A patent/EP3280798B1/en active Active
- 2016-04-07 WO PCT/GB2016/050973 patent/WO2016162675A1/en not_active Ceased
- 2016-04-07 CN CN201680020049.0A patent/CN107787364A/zh active Pending
- 2016-04-07 HK HK18110254.0A patent/HK1251009B/en unknown
- 2016-04-07 JP JP2017552992A patent/JP2018512150A/ja active Pending
- 2016-04-07 BR BR112017021700-7A patent/BR112017021700A2/pt not_active Application Discontinuation
-
2017
- 2017-10-02 IL IL254842A patent/IL254842B/en unknown
-
2019
- 2019-11-27 US US16/698,682 patent/US12023362B2/en active Active
-
2020
- 2020-12-02 JP JP2020199987A patent/JP7066812B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017021700A2 (pt) | 2018-07-24 |
| EP3280798B1 (en) | 2019-06-19 |
| CA2981925A1 (en) | 2016-10-13 |
| RU2720984C2 (ru) | 2020-05-15 |
| KR20180015113A (ko) | 2018-02-12 |
| RU2017134519A (ru) | 2019-04-04 |
| WO2016162675A1 (en) | 2016-10-13 |
| JP2021045152A (ja) | 2021-03-25 |
| US12023362B2 (en) | 2024-07-02 |
| US20180104288A1 (en) | 2018-04-19 |
| MX377211B (es) | 2025-03-07 |
| JP7066812B2 (ja) | 2022-05-13 |
| ES2743952T3 (es) | 2020-02-21 |
| IL254842A0 (en) | 2017-12-31 |
| GB201505860D0 (en) | 2015-05-20 |
| US20200155626A1 (en) | 2020-05-21 |
| MX2017012867A (es) | 2018-05-11 |
| RU2017134519A3 (https=) | 2019-10-10 |
| CN107787364A (zh) | 2018-03-09 |
| EP3280798A1 (en) | 2018-02-14 |
| HK1251009B (en) | 2020-06-26 |
| JP2018512150A (ja) | 2018-05-17 |
| KR102544032B1 (ko) | 2023-06-14 |
| CA2981925C (en) | 2025-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304820A (en) | Preparations and methods for the treatment of cancer | |
| IL258955B2 (en) | Cancer treatment preparations and methods | |
| IL266847B (en) | Cancer treatment methods that include tigit binding agents | |
| IL255333A0 (en) | Vaccines for the treatment and prevention of cancer | |
| IL255148A0 (en) | Cancer treatment methods | |
| IL254842B (en) | Therapeutic preparations and methods for use in cancer treatment | |
| SG11201700079VA (en) | Combination therapy compositions and methods for treating cancers | |
| IL254103A0 (en) | Compositions and methods for increasing the effectiveness of cancer treatment | |
| ZA201900960B (en) | Methods and compositions for the treatment of cancer | |
| SG11201706371VA (en) | Compositions and methods of tumor treatment utilizing nanoparticles | |
| IL256523A (en) | Compositions and methods for treating cancer | |
| IL255638A (en) | Compositions and methods for treating cancer | |
| IL247586A0 (en) | Use of Aribolin and mtor inhibitors as a combined treatment for cancer | |
| IL266486A (en) | Pharmaceutical preparations and methods for cancer treatment | |
| ZA201808232B (en) | Compositions and methods for the treatment of cancer | |
| ZA201802376B (en) | Compositions and methods for treatment of homocystinuria | |
| GB201511799D0 (en) | Composition and methods of treatment | |
| SG10202001388YA (en) | Use of ureidomustine (bo-1055) in cancer treatment | |
| IL255169A0 (en) | Treatment combination of an anti-pogatactic factor and an immunotherapy factor and compounds for the treatment of cancer | |
| SG11202000724XA (en) | Methods and compositions for the treatment of cancer | |
| IL255168A0 (en) | Treatment combination of an anti-pogatactic factor and an anti-cancer factor and compounds for the treatment of cancer | |
| SG10201912086QA (en) | Compositions and methods for treating cancer | |
| IL274866A (en) | Preparations and methods for the treatment of cancer | |
| HK1260504A1 (en) | Compositions and methods for treatment of cancer | |
| GB201418640D0 (en) | Agents and methods for treatment of cancer |